---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104014"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:50:03.839130+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%

## Summary
- Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.
- Adjusted EBITDA $15.2M (margin 31.1%), up 19.1% YoY; benefit from Q3 shift of annual marketing event and 503B vertical integration.
- CEO announced organizational restructuring in early May to accelerate new provider and clinic growth; new leadership and upgraded sales compensation.
- Q2 revenue decreased slightly YoY, but profitability and margins expanded significantly.

## SEC filing metadata
- accession: 0000950170-25-104014
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/0000950170-25-104014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/btmd-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104014
- JSON: https://secwatch.observer/filing/0000950170-25-104014.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.